Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer
Abstract Immune checkpoint inhibitors (ICIs) are standard-of-care as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC) without actionable oncogenic driver mutations. While clinical trials demonstrated benefits of ICIs over chemotherapy, variation in outcomes across patients ha...
Main Authors: | Ying Li, Matthew Brendel, Ning Wu, Wenzhen Ge, Hao Zhang, Petra Rietschel, Ruben G. W. Quek, Jean-Francois Pouliot, Fei Wang, James Harnett |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-10-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-20061-6 |
Similar Items
-
Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy
by: Ge W, et al.
Published: (2022-11-01) -
Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer
by: Josephine Louella Feliciano, et al.
Published: (2023-04-01) -
Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapy—Proof-of-Concept Animal Study
by: Benjamin Spieler, et al.
Published: (2022-05-01) -
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
by: Courèche Kaderbhaï, et al.
Published: (2019-02-01) -
Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
by: Yu Lu, et al.
Published: (2023-01-01)